2022-02-23

Midas Pharma receives CEP for Propofol

Midas Pharma was recently granted a Certificate of Suitability (CEP) for the active pharmaceutical ingredient (API) Propofol by the European Directorate for the Quality of Medicines (EDQM) and, with its European-based manufacturer, is one of the few European sources for this important API.

Midas Pharma is now -with its European-based manufacturer- one of a few European sources for this important API, which recently faced supply shortages during the COVID-19 pandemic.

At Midas Pharma, we are particularly proud of the fact that our Propofol can be stored and delivered at ambient conditions and does not require cooled conditions.

Propofol is one of the most widely used anesthetics in the world, as it is especially popular because of its few side effects and good tolerability.

If you are interested in more information about the product, please feel free to contact us.

Your Contact

Dr. Matthias Hassemer

Dr. Matthias Hassemer

Custom Synthesis & Technology Transfer
Head of Product Management

Midas Pharma GmbH
Rheinstr. 49
55218 Ingelheim
Germany
Send E-Mail

Share this page